trending Market Intelligence /marketintelligence/en/news-insights/trending/n0pocafmw2wz4_g2epn4vg2 content esgSubNav
In This List

Alder Biopharmaceuticals names interim CEO


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Alder Biopharmaceuticals names interim CEO

Alder Biopharmaceuticals Inc. appointed Paul Cleveland as interim president and CEO, effective March 20.

Cleveland will continue to serve as a director of Alder Biopharmaceuticals. His appointment was made after Randall Schatzman and the company's board decided that it was the right time for Schatzman to step down as president, CEO and director.

Schatzman has agreed to serve as a consultant to Alder Biopharmaceuticals for an interim period to ensure a smooth transition.

Alder Biopharmaceuticals has retained Russell Reynolds Associates, an executive search firm, to assist in the search for a permanent successor.

Cleveland currently serves as board chairman of Adverum Biotechnologies Inc., where he previously served as the president and CEO.

Bothell, Wash.-based Alder Biopharmaceuticals is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes therapeutic antibodies in the U.S., Australia and Ireland.